Search by PDG name  



      Official symbol:  TOP2A
      Full name:  DNA topoisomerase II alpha
      Location:  17q21.2
      Also known as:  TOP2
      Entrez ID:  7153
      Ensembl ID:  ENSG00000131747
      Summary:  This gene encodes a DNA topoisomerase, an enzyme that controls and alters the topologic states of DNA during transcription. This nuclear enzyme is involved in processes such as chromosome condensation, chromatid separation, and the relief of torsional stress that occurs during DNA transcription and replication. It catalyzes the transient breaking and rejoining of two strands of duplex DNA which allows the strands to pass through one another, thus altering the topology of DNA. Two forms of this enzyme exist as likely products of a gene duplication event. The gene encoding this form, alpha, is localized to chromosome 17 and the beta gene is localized to chromosome 3. The gene encoding this enzyme functions as the target for several anticancer agents and a variety of mutations in this gene have been associated with the development of drug resistance. Reduced activity of this enzyme may also play a role in ataxia-telangiectasia. [provided by RefSeq, Jul 2010]


  Overall distribution
  Tissue specific distribution
Expression restricted in 17 cancer type(s)
Cancer specific in breast cancer subtype (Basal; ER; Her2; Lum)

  Overall distribution
  Tissue specific distribution
Gscore (Amp):  0.00  
Gscore (Del):  0.00  

  Overall distribution
  Tissue specific distribution
Mscore:  0.20  (Driver)
Recurrently mutated in 3 cancer type(s)

  Tissue specific
Total fusion occurrence:  3  
Fusions detected in 2 cancer type(s)

  Tissue specific

      Functional class:  Enzyme
      JensenLab PubMed score:  722.97  (Percentile rank: 93.43%)
      PubTator score:  609.25  (Percentile rank: 94.46%)
      Target development/druggability level:  TclinThese targets have activities in DrugCentral (ie. approved drugs) with known mechanism of action.
      Tractability (small molecule):  Clinical PrecedenceTargets with drugs in phase II or above; Pre-clinical targets
      Tractability (antibody):  Clinical PrecedenceTargets with drugs in phase II or above; Pre-clinical targets


Contact us | | Terms & Conditions.
Copyright © 2020 University of Pennsylvania. All Rights Reserved.